NBTX

NBTX

USD

Nanobiotix S.A. American Depositary Shares

$19.330+0.560 (2.983%)

Preço em tempo real

Healthcare
Biotecnologia
França

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$18.770

Máximo

$20.261

Mínimo

$18.580

Volume

0.07M

Fundamentos da empresa

Capitalização de mercado

1.1B

Setor

Biotecnologia

País

France

Estatísticas de negociação

Volume médio

0.08M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $2.76Atual $19.330Máximo $30.35

Notícias relacionadas

GlobeNewswire

NANOBIOTIX to Participate in Investor Conferences the Week of November 10th

PARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand

Ver mais
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
GlobeNewswire

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial

Ver mais
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
GlobeNewswire

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand

Ver mais
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.